EUVIMEDEUVIMED entdecken
Multizentrische Studie

Short‐Term Feasibility of Transseptal Mitral Valve Replacement in China

Yi Zhang iD, Fei Chen, Yijun Yao, Zhongkai Zhu, Xi Li iD, Zhengang Zhao, Yuan Feng, Guangyuan Song iD, Ling Tao iD, Bo Yu iD, Chunlin Yin, Yan Wang iD und 3 weitere

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31685 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Yi Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Valve Prosthesis Implantation, Mitral Valve, Cardiac Catheterization. Die Arbeit nennt 30 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China (U23A20395, 82170375, and 82300570); Sichuan Science and Technology Program (2024NS….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds Significant mitral regurgitation (MR) is common worldwide, yet surgical correction rates remain low due to high‐risk patient profiles. Transseptal mitral valve replacement (TSMVR) has emerged as a minimally invasive alternative, but its feasibility in Asian populations remains underexplored.

Aims

This study assessed the short‐term feasibility of the HighLife TSMVR system for treating symptomatic MR in China.

Methods

This prospective study included seven centers in China, integrating data from multicenter and localized cohorts with identical inclusion criteria. Patients with symptomatic MR (≥ 3+) and high surgical risk were included, excluding those with unsuitable anatomy for the HighLife system. Preprocedural imaging was centrally adjudicated, and 30‐day outcomes were analyzed using R software (version 4.4.0).

Results

Twenty‐two patients (median age 70.5 years; 45.5% male) underwent the procedure. The predicted median mortality risk was 6.39%, with secondary MR in 81.8% of cases. Technical success was 95.5% (21/22). Median durations of valve delivery, ring closure, transseptal puncture, and looping were 4.00, 8.50, 22.25, and 42.75 min, respectively and 22.73% cases of tele‐proctoring. One patient required conversion to transcatheter aortic valve replacement, and two deaths occurred within 30 days. Significant improvements were observed in New York Heart Association class ( p = 0.033) and MR severity ( p < 0.001).

Conclusions

The HighLife TSMVR system demonstrated safety and efficacy in treating symptomatic MR in high‐risk Chinese patients, supporting its potential clinical applicability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart Valve Prosthesis ImplantationMitral ValveCardiac CatheterizationHumansMaleFemaleFeasibility StudiesProspective StudiesChinaAgedTreatment OutcomeTime FactorsMiddle AgedHeart Valve ProsthesisRisk FactorsRecovery of FunctionAged, 80 and overProsthesis Design

Stichwörter der Autor:innen

bioprosthetic mitral valvemitral regurgitationtransfemoral mitral valve replacementtransseptal mitral valve replacement

Autor:innen und Institutionen

  • Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
  • Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Cardiac Structure and Function Research Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
  • Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

ORCID-Profile: Yi Zhang, Xi Li, Guangyuan Song, Ling Tao, Bo Yu, Yan Wang, Jianan Wang

Förderung

  • This work was supported by the National Natural Science Foundation of China (U23A20395, 82170375, and 82300570); Sichuan Science and Technology Program (2024NS…

Zitieren

APA

Zhang, Y., Chen, F., Yao, Y., Zhu, Z., Li, X., Zhao, Z., Feng, Y., Song, G., Tao, L., Yu, B., Yin, C., Wang, Y., Wang, J., Piazza, N., & Chen, M. (2025). Short‐Term Feasibility of Transseptal Mitral Valve Replacement in China. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31685

Vancouver

Zhang Y, Chen F, Yao Y, Zhu Z, Li X, Zhao Z, et al. Short‐Term Feasibility of Transseptal Mitral Valve Replacement in China. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31685

BibTeX
@article{Zhang2025,
  author = {Zhang, Yi and Chen, Fei and Yao, Yijun and Zhu, Zhongkai and Li, Xi and Zhao, Zhengang and Feng, Yuan and Song, Guangyuan and Tao, Ling and Yu, Bo and Yin, Chunlin and Wang, Yan and Wang, Jianan and Piazza, Nicolo and Chen, Mao},
  title = {Short‐Term Feasibility of Transseptal Mitral Valve Replacement in China},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31685}
}
Kostenlos starten →